Abstract

The need to alleviate pain is among the first recorded uses for medicines, dating back to the onset of the Neolithic period. The need persists and many of today's best-known drugs (e.g. aspirin, acetaminophen, morphine) are included within this category. An analysis of FDA-approved new molecular entities (NMEs) for pain and anesthesia reveals a fluctuating rate of new introductions, which has plummeted in recent years. The largest emphasis has been placed on acute pain, largely targeting G-protein-coupled receptors and a relatively narrow subset of molecular pathways. NMEs targeting anesthesia tend to focus on channels and four molecular pathways capture a large majority of NMEs for this indication.

Original languageEnglish
Pages (from-to)3-6
Number of pages4
JournalDrug Discovery Today
Volume20
Issue number1
DOIs
StatePublished - Jan 2015

Fingerprint

Dive into the research topics of 'An analysis of FDA-approved drugs for pain and anesthesia'. Together they form a unique fingerprint.

Cite this